

PLENARY SESSIONS	PARALLEL SESSIONS	NETWORKING EVENT	ACADEMY
INDUSTRY SUPPORTED SESSION Not Included in the Main Event CME / CPD Credit	PRE-CONGRESS COURSES		

14th International Congress on Autoimmunity Program

Friday, 17 May 2024

	HALL A	HALL B	HALL C
09:00 - 12:00		PRE-CONGRESS WORKSHOP Imaging in autoimmune rheumatic diseases Iris Eshed, Israel, Gideon Flusser, Israel	PRE-CONGRESS WORKSHOP Ultrasound in autoimmune rheumatic diseases Carlo Perricone, Italy, Alexandra Balbir-Gurman, Israel, Alojzija Hocevar, Slovenia
12:15 - 17:15			ACADEMY OF AUTOIMMUNITY Autoimmunity up-to date 12:15 - 12:45 Autoimmunity vs autoinflammation: same or different? Zoltán Szekanecz, Hungary 12:45 - 13:15 Regulatory T cells and Autoimmunity. Mitesh Dwivedi, India 13:15 - 13:45 The significance of cytokines in autoimmune diseases. Dimitrios Bogdanos, Greece  SHORT BREAK 13:45 - 14:00  14:00 - 14:30 Primary biliary cholangitis (PBC)-a classical autoimmune disease. Zigmund Ehud, Israel 14:30 - 15:00 Thyroid autoimmunity in other autoimmune diseases. Alessandro Antonelli, Italy  SHORT BREAK 15:00 - 15:15  15:15 - 15:45 Comorbidities in autoimmune diseases - state of the art. Lessons learnt from big data analyses. Amital Howard, Israel 15:45 - 16:15 IIVIG as pancea in autoimmune diseases. Maria Giovanna Danielli, Italy 16:15-16:45 Skin Autoimmune Diseases Razzaque Ahmed, USA 16:45- 17:15 Prediction in Autoimmunity Luis E. Andrade, Brazil
17:15-17:45	SHORT BREAK		
17:45-19:30	OPENING CEREMONY & WELCOME RECEPTION Ceremony of Lifetime Contribution to Autoimmunity Awards		

**Saturday, 18 May 2024**

	HALL A	HALL B	HALL C
08:00 – 10:00 (2 hours)	<p><b>PLENARY 1</b>  <b>Chairs:</b> Tadej Avcin, Slovenia, Andrea Doria, Italy, Howard Amital, Israel  <b>1. Uveitis in autoimmune diseases - why the uvea is so prevalently involved.</b>  Vicktoria Vishnevskia-Dai, Israel 30 min  <b>2. What's still unresolved in Hughes Syndrome /Anti phospholipid syndrome.</b>  Graham Hughes, UK 30 min  <b>3. Genetic predisposition to autoimmunity and autoinflammation.</b> Bodo Grimbacher 30 min  -----  <b>Challenge the Expert</b>  <b>Chairs:</b> Yehuda Shoenfeld, Christopher Edwards  <b>Experts:</b>  Iris Eshed, Radiology, Israel 15 min  <b>1. CT vs. MRI. Who needs CT when there is MRI? Is there a future for CT imaging?</b>  <b>2. Diffuse idiopathic skeletal hyperostosis, is it an inflammatory disease?</b>  <b>3. Is there a difference between SAPHO (sacroiliitis, Acne Pustulosis, Hyperostosis, Osteitis) and CRMO (chronic relapsing multifocal osteomyelitis)?</b>  Dennis McGonagle, Rheumatology, UK 15 min  <b>1. Why dosent Interleukin-23 blockade work in Ankylosing Spondylitis</b>  <b>2. What is the difference between Ankylosing Spondylitis and axial Psoriatic Arthritis in terms of pathogenesis</b>  <b>3. Will Faecal microbiotal transplants revolution Spondyloarthropathy and prevention?</b></p>		
10:00 – 10:30 (30 min)	<b>COFFEE BREAK, EXHIBITION, POSTER VIEWING</b> <b>New Book signing session 1 (10:05-10:25, Exhibition area)</b> <b>'Autoimmunity, COVID-19, Post-COVID19 Syndrome and COVID-19 Vaccination'</b> <b>Participants: Yehuda Shoenfeld, Arad Dotan</b>		
10:30 – 12:00 (1,5 hour)	<p><b>PS01 APS: What's new in antiphospholipid syndrome?</b>  <b>Chair 1</b> Graham Hughes, UK  <b>Chair 2</b> TBA  <b>Chair 3</b> Sonja Praprotnik, Slovenia  <b>1. New classification criteria for the antiphospholipid syndrome.</b> Ricard Cervera, Spain 15 min  <b>2. Do the last classification criteria change our routine approach to Anti Phospholipid Syndrome?</b> Pier Luigi Meroni 15 min  <b>3. Time to treat to target in APS.</b> Savino Sciascia, Italy 15 min  <b>4. Challenges in pediatric antiphospholipid syndrome.</b> Tadej Avcin, Slovenia 15 min  <b>5. Implementation of the new ACR/EULAR classification criteria for antiphospholipid syndrome in clinical practice.</b> Saša Čučnik, Slovenia 15 min  <b>6. Abstract ID 378 INTEGRATING AB2GPI-D1ANTIBODIES INTO THE CLINICAL PRACTISE: AN ITALIAN MULTI-CENTER EXPERIENCE,</b> Maria Infantino 15 min</p>	<p><b>PS02 COVID-19, Post COVID Syndrome and Autoimmunity</b>  <b>Chair 1</b> Carmen Scheibenbogen, Germany  <b>Chair 2</b> Natalia Gavrilova, Russia  <b>Chair 3</b> Zaiga Nora-Krūkle, Latvia  <b>1. Myositis in the COVID-19 Era-Mere coincidence.</b> Dennis McGonagle, UK 15 min  <b>2. COVID-19, Post COVID syndrome, "ME/CFS" Vaccines and Autoimmune Adverse Effects.</b> Carmen Scheibenbogen, Germany 15 min  <b>3. Severity of neurological long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors - single center experience.</b> Nina Babel, Germany 15 min  <b>4. New Onset Autoimmune Diseases after the Sputnik Vaccine.</b> Olga Vera-Lastra, Mexico 15 min  <b>5. IVIG as a treatment option for the post-COVID-19 condition. Personal experience.</b> Natalia Gavrilova, Russia 15 min  <b>6. Abstract ID 14 RISK FACTORS FOR MODERATE TO SEVERE COVID-19 INFECTION IN SYSTEMIC LUPUS ERYTHEMATOSUS</b> Wendell Oliver Española, 15 min</p>	<p><b>PS03 Chimeric antigen receptor (CAR) T-cell and novel therapies in autoimmune diseases</b>  <b>Chair 1</b> Sylviane Muller, France  <b>Chair 2</b> Luis E. Andrade, Brazil  <b>Chair 3</b> TBA  <b>Session dedicated in memory of Prof. Alan Wiik</b>  <b>1. Use of CART-T cells in systemic lupus erythematosus.</b> Dominique Farge, France 15 min  <b>2. Cell therapy approaches for autoimmune diseases.</b> Luis E. Andrade, Brazil 15 min  <b>3. Novel Therapy Cannabis in Autoimmunity.</b> Howard Amital, Israel 15 min  <b>4. How therapeutic peptides work in autoimmune diseases: P140 peptide corrects failures in secondary lymphoid organs with an impact on remote tissues.</b> Sylviane Muller, France 15 min  <b>5. Glycan as new immunomodulatory targets in SAIDs.</b> António Marinho, Portugal 15 min  <b>6. Predicting treatment response according to RNA gene expression in systemic sclerosis, from bench to bedside.</b> Doron Rimar, Israel 15 min</p>
12:00 – 14:00 (2 hours)	<b>INDUSTRY SUPPORTED SESSION 12:15 - 13:45</b> <b>NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT</b>	<b>INDUSTRY SUPPORTED SESSION 12:15 - 13:45</b> <b>NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT</b>	<b>LUNCH BREAK, EXHIBITION, SHORT ORAL PRESENTATIONS, E-POSTER VIEWING</b>

14:00 – 15:30 (1,5 hour)	<p><b>PS04 LUPUS - 2025</b>  <b>Chair 1</b> Mentago Li, China  <b>Chair 2</b> Luís Inês, Portugal  <b>Chair 3</b> Mariele Gatto, Italy</p> <p><b>1. Belimumab vs. Anifrolumab in SLE: which drug in which patient?</b> Andrea Doria, Italy 15 min  <b>2. Challenges of systemic lupus erythematosus associated pulmonary arterial hypertension.</b> Mentago Li, China 15 min  <b>3. Flares in SLE: How to predict and measure in daily clinical practice?</b> Luís Inês, Portugal 15 min  <b>4. Immune complex analyses in systemic lupus erythematosus.</b> Johan Rönnelid, Sweden 15 min  <b>5. TBA</b>  <b>6. Abstract ID 483 PHENOTYPE AND LONG-TERM DAMAGE ACCRUAL IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: THE ROLE OF SEX AND AGE AT ONSET</b> Luca Moroni, 15 min</p>	<p><b>PS05 Pregnancy and Autoimmunity</b>  <b>Chair 1</b> Angela Tincani, Italy  <b>Chair 2</b> Natasa Toplak, Slovenia  <b>Chair 3</b> Caterina De Carolis, Italy</p> <p><b>1. The joints in the pregnant lady.</b> Iris Eshed, Israel 15 min  <b>2. Pregnancy and rare systemic autoimmune diseases.</b> Marta Mosca, Italy 15 min  <b>3. Gender medicine in autoimmunity: from bench to bedside and more.</b> Roberta Gualtierotti, Italy 15 min  <b>4. Thyroid, autoimmune diseases, recurrent spontaneous abortion and RAFS.</b> Caterina De Carolis, Italy 15 min  <b>5. Abstract ID 267 ASSESSMENT OF OVARIAN DYSFUNCTION IN ADOLESCENT FEMALE PATIENTS WITH SEVERE RHEUMATIC DISEASE RECEIVING CYCLOPHOSPHAMIDE</b> Cansu Ayten Tatar, 15 min  <b>6. Abstract ID 347 A CASE OF THROMBOTIC MICROANGIOPATHY DURING PREGNANCY IN A PATIENT WITH TAKAYASU ARTERITIS AND LA POSITIVITY: SUCCESSFUL MANAGEMENT OF A SUBSEQUENT PREGNANCY WITH CERTOLIZUMAB PEGOL</b> Liala Moschetti 15 min</p>	<p><b>PS06 Systemic Sclerosis, Psoriasis and Spondyloarthritis</b>  <b>Chair 1</b> Abdulla Watad, Israel  <b>Chair 2</b> Dennis McGonagle, UK  <b>Chair 3</b> Alexandra Balbir, Israel</p> <p><b>1. Systemic sclerosis: from pathophysiology to novel therapeutic approaches.</b> Katja Lakota, Slovenia 15 min  <b>2. Natural history of systemic sclerosis: a 15-years single-center experience.</b> Dimitrios Bogdanos, Greece 15 min  <b>3. Connective tissue diseases associated PAH.</b> Luc Mouthon, France 15 min  <b>4. Complete resolution of gastric antral vascular ectasia in systemic sclerosis after autologous stem cell transplantation - a case series with long term results.</b> Doron Rimar, Israel 15 min  <b>5. Abstract ID30 CARDIOVASCULAR OUTCOMES OF SYSTEMIC TREATMENTS IN PSORIASIS AND PSORIATIC ARTHRITIS: A COMPARATIVE ANALYSIS OF BIOLOGICAL AGENTS</b> Arad Dotan, 15 min  <b>6. Abstract ID39 A MACHINE LEARNING TOOL FOR THE EARLY IDENTIFICATION OF UNDIAGNOSED PSORIATIC ARTHRITIS PATIENTS. IS IT POSSIBLE?</b> Jonathan Shapiro 15 min</p>
15:30 – 15:45 (15 min)	<b>SHORT BREAK</b>		
15:45 – 16:45 (1 hour)	<p><b>PS07 Mechanisms in Autoimmunity (Part 1)</b>  <b>Session dedicated in memory of Prof. Noel Rose</b>  <b>Chair 1</b> George Wick, Austria  <b>Chair 2</b> Ferdinando Nicoletti, Italy  <b>Chair 3</b> Dimitrios Bogdanos, Greece</p> <p><b>1. Educating Medical Students to Think Autoimmunity.</b> Arnon Afek, Israel 10 min  <b>2. Triggering of Autoimmunity by Mechanical Stress.</b> George Wick, Austria 10 min  <b>3. Galectins in autoimmune diseases friends or foes?</b> Ferdinando Nicoletti, Italy 15 min  <b>4. Vitamin D in Autoimmunity.</b> Ifigania Kostoglou–Athanassiou, Greece 10 min  <b>5. RA and type 2 diabetes: the role of the metabolic inflammation.</b> Roberto Giacomelli, Italy 10 min  <b>6. Defective lysosomes and lysosomal autophagy in lupus.</b> Sylviane Muller, France 10 min</p>	<p><b>DEBATE 01 Glucocorticoids in the Management of RA</b>  <b>Chair:</b> Yehuda Shoenfeld, Israel, Johan Rönnelid, Sweden  <b>Yes:</b> Maurizio Cutolo, Italy  <b>No:</b> György Nagy, Hungary</p>	<p><b>PS08 Vasculitis - update</b>  <b>Chair 1</b> Gleb Slobodin, Israel  <b>Chair 2</b> Alojzija Hočevár, Slovenia  <b>Chair 3</b> Jan Damoiseaux, The Netherlands</p> <p><b>1. Innate immunity in ANCA-associated vasculitis.</b> Jan Damoiseaux, The Netherlands 10 min  <b>2. CNS vasculitis - update.</b> Gisele Zandman-Goddard, Israel 10 min  <b>3. Adult IgA vasculitis.</b> Alojzija Hočevár, Slovenia 10 min  <b>4. Polymyalgia rheumatica (PMR) or late onset PMR-like RA - a diagnostic conundrum.</b> Gleb Slobodin, Israel 10 min  <b>5. Predictors of remission and flare in patients with polymyalgia rheumatica.</b> Carlo Perricone, Italy 10 min  <b>6. Pathways deregulated in giant cell arteritis by gene expression profiling in temporal artery biopsies.</b> Dr.ssa Stefania Croci, Italy 10 min</p>
16:45 – 17:15 (30 min)	<b>COFFEE BREAK, EXHIBITION, POSTER VIEWING</b>		
17:15 – 18:30 (1 hour 15 min)	<p><b>PANEL DISCUSSION 01. Hippocrates versus ChatGPT</b>  <b>Discussants:</b> Howard Amital, Israel and Dimitrios Bogdanos, Greece vs Yoad Dvir, Israel</p> <p><b>1) Diagnostic dilemma</b> 25 min  <b>2) Therapeutic dilemma</b> 25 min  <b>3) HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: ARTIFICIAL INTELLIGENCE AND ITS ROLE IN AIDING DIAGNOSIS.</b> Antonio Lamas, Portugal 25 min</p>	<p><b>DEBATE 02 What is the Best Instrument To Measure Disease Activity in SLE?</b>  <b>Chair:</b> Andrea Doria, Italy  <b>BILAG:</b> Edward Vital, UK  <b>SLE-DAS:</b> Luís Inês, Portugal</p>	<p><b>PS09 Sjögren syndrome and novel therapies in autoimmunity</b>  <b>Chair 1</b> Roberto Gerli, Italy  <b>Chair 2</b> Athanasios Tzioufas, Greece  <b>Chair 3</b> Piercarlo Sarzi-Puttini, Italy</p> <p><b>1. Sjögren's syndrome towards stratified Medicine.</b> Athanasios Tzioufas, Greece 15 min  <b>2. Epidemiology of Sjögren syndrome</b> Roberto Gerli, Italy 15 min  <b>3. Accrual damage in Sjogren Syndrome.</b> Roberto Giacomelli, Italy 15 min  <b>4. Mixed connective tissue diseases: classification criteria, clinical presentation and prognosis.</b> Luc Mouthon, France 15 min  <b>5. Abstract ID 681 ANTI-RO52 ANTIBODIES AND DISEASE SEVERITY IN PATIENTS WITH SJÖGREN'S DISEASE.</b> Eleonore Bettacchioli 7.5 min  <b>6. Abstract ID 648 ADMINISTRATION OF A NOVEL IMMUNE CHECKPOINT MOLECULE TAPBPL AMELIORATES AUTOIMMUNE DISEASES IN MICE</b> Laijun Lai, 7.5 min</p>
19:00 – 20:00	<b>Talk with Professor in the Bar</b>		

**Sunday, 19 May 2024**

	HALL A	HALL B	HALL C
08:00 – 10:00	<b>PLENARY 2</b> <b>Chairs:</b> Koike Takao, Japan, Saša Čučnik, Slovenia, Dario Roccatello, Italy <b>1. New paradigms in the management of SLE.</b> Andrea Doria, Italy 30 min <b>2. Why we develop Autoimmune diseases?</b> Yehuda Shoenfeld, Israel 30 min <b>3. Daratumumab monotherapy for refractory lupus nephritis.</b> Dario Rocatello, Italy 30 min  ----- <b>Challenge the Expert</b> <b>Chairs:</b> Yehuda Shoenfeld, Christopher Edwards <b>Experts:</b> Xavier Bossuyt 15 min <b>1. How can reporting of autoantibody test results be improved?</b> <b>2. Can we reliably measure autoantibodies that recognize conformational epitopes?</b> <b>3. Can the impact of autoantibodies in diagnostic criteria be upgraded?</b> Pier Luigi Meroni 15 min <b>1. Is the old statement 'one autoantibody/one disease' still satisfactory in 2024?</b> <b>2. Can we use the new diagnostic platforms for assessing the last classification criteria for autoimmune diseases?</b> <b>3. Can we look at an antiphospholipid panel for improving our diagnostic/prognostic power in APS?</b>		
10:00 – 10:30	COFFEE BREAK, EXHIBITION, POSTER VIEWING, New Book signing session 2 (10:05-10:25, Exhibition area) 'Infection and Autoimmunity' Participants: Prof. Yehuda Shoenfeld, Prof. Naim Mahroum		
10:30 – 12:00	<b>PS10 Infections and Autoimmunity</b> <b>Chair 1</b> Carlos Vasconcelos, Portugal <b>Chair 2</b> Naim Mahroum, Turkey <b>Chair 3</b> Savino Sciascia, Italy <b>1. Infection and Autoimmunity - concept and history, the pandemic of COVID-19.</b> Naim Mahroum, Turkey 15 min <b>2. Viral-induced networks and their link with the development of "neglected autoimmune diseases".</b> Otávio Marques, Brazil 15 min <b>3. Post infectious syndromes: spectrum and autoimmune mechanisms.</b> Carmen Scheibenbogen, Germany 15 min <b>4. Serious Infections in Autoimmune disease patients: experience of a single center cohort.</b> Carlos Vasconcelos, Portugal 15 min <b>5. The unique combination of gut microbiome and viral infection in FM patients.</b> Zaiga Nora-Krūkle, Latvia 15 min <b>6. Adaptive immunity in COVID-19 – two sides of the coin.</b> Nina Babel, Germany 15 min	<b>PS11 Autoimmune Syndrome Induced by Adjuvants (Shoenfeld's Syndrome)</b> <b>Chair 1</b> Jan Willem Cohen Tervaert, Canada <b>Chair 2</b> Luis Javier Jara, Mexico <b>Chair 3</b> Boris Gilburd, Israel <b>1. ASIA (Shoenfeld's syndrome) due to implants: a hype or a real phenomenon?</b> Jan Willem Cohen Tervaert, Canada 15 min <b>2. Hyperprolactinemia in ASIA after mineral oil injection and silicone breast implants.</b> Luis Javier Jara, Mexico 15 min <b>3. ASIA and silicone.</b> Gustavo Emilio Schenone, Argentina 15 min <b>4. Tattoo and Autoimmunity.</b> Amir Tanay, Israel 15 min <b>5. Is vaccination in children with immune mediated diseases safe and immunogenic?</b> Natasa Toplak, Slovenia 15 min <b>6. Exploring the exposome's influence on vaccination effectiveness.</b> Pedro Bastos, Sweden 15 min	<b>PS12 Autoimmunity in the Central Nervous System</b> <b>Chair 1</b> Ron Milo, Israel <b>Chair 2</b> Manuel Martinez-Lavin, Mexico <b>Chair 3</b> Miri Blank, Israel (tbc) <b>1. Better understanding the underlying mechanism of fibromyalgia syndrome using circulating extracellular vesicles.</b> Gilad Halpert, Israel 15 min <b>2. Fibromyalgia : neuroinflammation or autoimmunity?</b> Piercarlo Sarzi-Puttini, Italy 15 min <b>3. The different clinical manifestations of small fiber neuropathy.</b> Manuel Martinez-Lavin, Mexico 15 min <b>4. New B cell-targeted therapies for multiple sclerosis.</b> Ron Milo, Israel 15 min <b>5. The nervous system in rheumatoid arthritis.</b> Christopher Edwards, UK 15 min <b>6. Immune reconstitution therapy vs chronic immunomodulation or immunosuppression for MS and other neuroimmune diseases.</b> Dimitrios Karusis, Israel 15 min
12:00 – 14:00	<b>LUNCH BREAK, EXHIBITION, SHORT ORAL PRESENTATIONS, E-POSTER VIEWING,</b> <b>New Book signing session 3 (12:10 - 13:10, Exhibition area)</b> <b>'Adjuvants and Autoimmunity/ASIA Syndrome'</b> <b>Participants: Prof. Yehuda Shoenfeld, Prof. Abdulla Watad</b>	<b>INDUSTRY SUPPORTED SESSION 12:15 - 13:45</b> <b>NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT</b>	

14:00 – 15:30	<p><b>PS13 Rheumatoid Arthritis and Myositis (Muscles)</b>  <b>Chair 1</b> Christopher Edwards, UK  <b>Chair 2</b> Gleb Slobodin, Israel  <b>Chair 3</b> Olga Vera-Lastra, Mexico</p> <p>1. Ways to prevent difficult-to-treat RA. Gleb Slobodin, Israel 15 min  2. Efficacy and safety of JAK1 for the treatment of RA in real-life. Carlo Perricone, Italy 15 min  3. Inflammatory myopathies and ILD. Sonja Praprotnik, Slovenia 15 min  4. From fat to muscle- an unusual type of myositis - a case report and literature review. Milena Tocut, Israel 15 min ( abstract 120)  5. Correct nutrition as immunomodulatory co-therapy in rheumatoid arthritis. Maurizio Cutolo, Italy 15 min  6. Abstract ID 230 FUNCTIONAL CONNECTIVITY ASSOCIATED WITH RESPONSE TO BIOLOGICS IN RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS Yuichiro Fujieda 15 min</p>	<p><b>PS14 Therapeutic Challenges in Autoimmunity</b>  <b>Chair 1</b> Martin Aringer, Germany  <b>Chair 2</b> Gellerman Gary, Israel  <b>Chair 3</b> Doron Rimar, Israel</p> <p>1. Helminth derivative to treat autoimmunity. Miri Blank, Israel 15 min  2. News on Janus kinase (Jak) function and Jak inhibition in SLE. Martin Aringer, Germany 15 min  3. Autologous stem cell transplantation versus upfront combination therapy of rituximab and mycophenolate mofetil for progressive diffuse systemic sclerosis - 2 year outcomes. Doron Rimar, Israel 15 min  4. The use of stem cell therapies for Multiple Sclerosis and neuroinflammatory and neurodegenerative diseases. Dimitrios Karusis, Israel 15 min  5. Antibody-driven photodynamic and sonodynamic therapies: a look into the future of targeted medicine. Gary Gellerman, Israel 15 min  6. Functional consequences of immunological checkpoint inhibitor therapies on lymphocytes. Ulrich Sack, Germany 15 min</p>	<p><b>PS15 EASI Session: The new APS classification criteria: implications in clinical practice</b>  <b>Chair 1</b> Nicolla Bizarro, Italy  <b>Chair 2</b> Marcos Hoyos, Spain</p> <p>1. Assessment of the clinical domain within the new APS classification criteria. Denis Wahl, France 20 min  2. Laboratory classification criteria for APS are not the same as diagnostic laboratory criteria for APS. Katrien Devreese, Belgium 20 min  3. The impact of the new APS classification criteria on pregnancy morbidity. Savino Sciascia, Italy 20 min  4. Panel discussion 30 min</p>
15:30 – 15:45	SHORT BREAK		
15:45 – 16:45	<p><b>PS16 Big data, Prediction, Monitoring and Prevention</b>  <b>Chair 1</b> Gisele Zandman-Goddard, Israel  <b>Chair 2</b> Matthias Schneider, Germany  <b>Chair 3</b> Gideon Flusser, Israel</p> <p>1. Standardized core data sets. Matthias Schneider, Germany 15 min  2. Precision medicine in Lupus. Gisele Zandman-Goddard, Israel 15 min  3. Predictors of severe autoimmune haemolytic anaemia and severe thrombocytopenia in SLE. Bernardo Pons-Estel, Argentina 15 min  4. Autoantibodies and Precision Medicine. Luis E. Andrade, Brazil 15 min  5. Abs against the chemokine receptor CXCR3 as predictor for mortality in a population-based study. Hanna Grasshoff, Germany 15 min  6. Big Data in psoriasis. Howard Amital, Israel 15 min</p>	<p><b>DEBATE 03 Might Maintenance Therapy Be Discontinued Once Clinical Remission Is Achieved in ANCA-Associated Vasculitis</b>  <b>Chair:</b> Ricard Cervera, Spain, Piero Ruscitti, Italy  <b>No:</b> Carlo Salvarani, Italy  <b>Yes:</b> Dario Roccatello, Italy</p>	<p><b>PS17 Autoantibodies (ABS) - Prediction, Pathogenic and Prevention</b>  <b>Chair 1</b> Pier Luigi Meroni, Italy  <b>Chair 2</b> Michael Mahler, USA  <b>Chair 3</b> Xavier Bossuyt, Belgium</p> <p>1. Much more than anti-dsDNA antibodies for lupus nephritis. Pier Luigi Meroni, Italy 10 min  2. Autoimmunity, Immunodeficiency and Autoinflammation in a cohort of patients from a clinical immunology unit. Carlos Vasconcelos, Portugal 10 min  3. The stratification of autoimmune patients for personalized therapy: importance of flow cytometry. Christophe Jamin, France 10 min  4. Obesity in late adolescence and incidence of Type 1 diabetes in young adulthood. Arnon Afek, Israel 10 min  5. Abstract ID 692 TRANSCRIPTOMIC PROFILING REVEALS NOVEL INSIGHTS INTO THE CELLULAR PROTECTIVE FUNCTIONS OF THE DFS70/LEDGF NUCLEAR AUTOANTIGEN Carlos Casiano, 10 min  6. Abstract ID 221 REMISSION IN LUPUS IS AFFECTED BY COMORBIDITIES Abihai Lucas Hernández 10 min</p>
16:45 – 17:15	COFFEE BREAK, EXHIBITION, POSTER VIEWING		
17:15 – 18:30	<p><b>PANEL DISCUSSION 02 - Difficult cases in Autoimmunity</b>  <b>Panel:</b> Carlo Salvarani, Italy, Razzaque Ahmed, USA  <b>Presenter and Responder:</b> Carlo Perricone, Italy</p> <p>1. Case of overlapping EGPA/GPA 25 min  2. Case of alopecia universalis which improved at 1 month of treatment with JAK1 inhibitor upadacitinib 25 min  <b>Presenter and Responder:</b> Ricard Cervera, Spain  3. Case on LUPUS/C-APS 25 min  <b>Discussion</b></p>	<p><b>PS18 Cytokines and Autoimmunity</b>  <b>Chair 1</b> Pierre Miossec, France  <b>Chair 2</b> Luca Cantarini, Italy  <b>Chair 3</b> Oliver Distler, Switzerland</p> <p>1. IL-17, 25 years later. Pierre Miossec, France 15 min  2. IL-1beta inhibition in Adult onset Still's disease. Luca Cantarini, Italy 15 min  3. IL-6, the choroid plexus, and the pathogenesis of neuropsychiatric lupus. Chaim Putterman, Israel 15 min  4. The emerging role of macrophage migration inhibitory family of cytokines in autoimmune diseases. From pathogenesis to new treatments? Ferdinando Nicoletti, Italy 15 min  5. Abstract 894 A HUNDREDFOLD GREATER INDUCTION OF IL-23 FROM AXIAL ENTHESES BONE COMPARED TO PERIPHERAL ENTHESES AS AN EXPLANATION FOR IL-23 BLOCKADE FAILURE IN ANKYLOSING SPONDYLITIS BUT NOT PERIPHERAL PSORIATIC ARTHRITIS Paula David 15 min.</p>	<p><b>PS19 Systemic Autoimmunity, Liver and Gastrointestinal</b>  <b>Chair 1</b> Aaron Lerner, Israel  <b>Chair 2</b> Roberta Gualtierotti, Italy  <b>Chair 3</b> Zigmund Ehud, Israel</p> <p>1. Cross-Reactivity and sequence similarity between microbial transglutaminase and human antigens: expanding the exposome of autoimmune diseases. Aaron Lerner, Israel 15 min  2. Systemic treatment for alopecia areata. Gasper Markelj, Slovenia 15 min  3. Abstract ID 216 CHOLANGITIS INDUCED BY IMMUNE CHECKPOINT INHIBITORS: ANALYSIS OF PHARMACOVIGILANCE DATA Alexandre Maria, 10 min  4. Abstract ID 433 SERUM ANTICARDIOLIPIN ANTIBODIES AND ENDOTHELIN-1 AS MARKERS OF PORTAL HYPERTENSION IN PRIMARY BILIARY CHOLANGITIS Alicja Bauer, 10 min  5. Abstract ID 332 HUMAN ANTIMICROBIAL GLYCOPROTEIN-2 EXPRESSED IN BRUNNER GLANDS – A PUTATIVE AUTOIMMUNE TARGET OF CROHN'S AND CELIAC DISEASE Dirk Roggenbuck 10 min  6. Abstract ID 754 IL-10-PRODUCING REGULATORY CELLS IMPACT ON CELIAC DISEASE EVOLUTION Carmen Gianfrani 10 min</p>
	Faculty Dinner		

**Monday, 20 May 2024**

	HALL A	HALL B	HALL C
08:00 – 10:00	<p><b>PLENARY 3</b>  <b>Chairs:</b> Angela Tincani, Italy, Christopher Edwards, UK, Arnon Afek, Israel  <b>1. MAI award winners 2023, 10 minutes each</b></p> <p><b>2. Prediction and prevention of autoimmunity (Using example of Rheumatoid Arthritis, Prediction Models, Review of status of prevention trials).</b> Michael Mahler, USA 30 min</p> <p><b>3. Paraneoplastic Autoimmune Laminin-332 Syndrome (PALS).</b> Razzaque Ahmed, USA 30 min          -----  <b>Challenge the Expert</b>  <b>Chairs:</b> Yehuda Shoenfeld, Christopher Edwards  <b>Experts:</b>          Alessandro Antonelli, Italy 15 min  <b>1. Which is the prevalence of systemic autoimmune disorders in patients with autoimmune thyroid diseases, and which is the impact on the health of these patients?</b>  <b>2. Which are the new therapies for Graves' ophthalmopathy, and which is the impact on the disease?</b>  <b>3. Which is the impact of Covid-19 infection in patients with thyroid autoimmunity?</b> Andrea Doria, Italy 15 min  <b>1. Is it common to achieve the T2T goals in SLE patients?</b>  <b>2. Why should we use biologics early in SLE patients?</b>  <b>3. Can we withdraw low-dose-glucocorticoid in remitted SLE patients?</b></p>		
10:00 – 10:30	<b>COFFEE BREAK, EXHIBITION, POSTER VIEWING</b>		
10:30 – 12:00	<p><b>PS20 Novel Autoimmune Diseases</b>  <b>Chair 1</b> Ivica Lazurova, Slovakia  <b>Chair 2</b> Ora Shovman, Israel  <b>Chair 3</b> Michael Ehrenfeld, Israel  <b>1. Hypocryoglobulinaemia: a new entity?</b> Dario Roccatello, Italy 15 min  <b>2. Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications.</b> Piero Ruscitti, Italy 15 min  <b>3. An update on CPPD diagnosis and management.</b> Ora Shovman, Israel 15 min  <b>4. What's immune in ankylosing spondylitis? (or difficult cases)</b> Abdulla Watad, Israel 15 min  <b>5. Acquired hemophilia: a too often overlooked autoimmune disease.</b> Roberta Gualtierotti, Italy 15 min  <b>6. Abstract ID 263 AUTOIMMUNITY AND ENDOMETRIOSIS: POTENTIAL RELEVANCE OF A NOVEL IMMUNOMODULATING COMPOUND</b> Michael Agrez, 15 min</p>	<p><b>PS21 Systemic Sclerosis</b>  <b>Chair 1</b> Alexandra Balbir-Gurman, Israel  <b>Chair 2</b> Oliver Distler, Switzerland  <b>Chair 3</b> Yaniv Sherer, Israel  <b>1. When to start or escalate treatment in SSc-ILD.</b> Oliver Distler, Switzerland 20 min  <b>2. Abstract ID 551 ASSOCIATION OF CD 19 WITH RESPIRATORY FUNCTIONAL STATUS IN PATIENTS WITH PULMONARY FIBROSIS AND SYSTEMIC SCLEROSIS</b> Alfredo Garcia 10 min  <b>3. Abstract ID 487 CHRONIC FATIGUE AS A MARKER OF MITOCHONDRIAL DYSFUNCTION, HYPOXIC STRESS AND VASCULAR REMODELLING IN EARLY SYSTEMIC SCLEROSIS</b> Charmaine van Eeden 10 min  <b>4. Abstract ID 638 SHAPING MONOCYTE PATHOGENICITY IN SYSTEMIC SCLEROSIS: THE CONVERGENCE OF AT1R AUTOANTIBODIES AND EXTRACELLULAR VESICLES</b> Alexander Hackel 10 min  <b>5. Abstract ID 689 ANALYSIS AND CHARACTERIZATION OF PLASMA EXTRACELLULAR VESICLES IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS</b> Stelvio Tonello 10 min  <b>6. Abstract ID 699 THE ROLE OF CXCL4-L1, THE NON-ALLELIC VARIANT OF CXCL4, IN SYSTEMIC SCLEROSIS</b> Loredana Frasca 10 min  <b>7. Abstract ID 746 ANTIOXIDANT ENZYMES IN SYSTEMIC SCLEROSIS</b> Neža Brezovec 10 min</p>	<p><b>PS22 Novel Approaches to Handle Autoimmune Diseases</b>  <b>Chair 1</b> Carlo Salvarani, Italy  <b>Chair 2</b> Gilad Halpert, Israel  <b>Chair 3</b> David Naor, Israel  <b>1. Modulation of autoimmune diseases by targeting the Nfr2-HO1-CO pathway.</b> Ferdinando Nicoletti, Italy 15 min  <b>2. Acupuncture therapy of Autoimmune diseases – State of the Art.</b> Dorit Gamus, Israel 15 min  <b>3. The potential of autologous patient-derived circulating extracellular vesicles to improve drug delivery in inflammatory rheumatic autoimmune diseases.</b> Gilad Halpert, Israel 15 min  <b>4. What's new in the treatment of large vessel vasculitis.</b> Carlo Salvarani, Italy di Reggio Emilia e UNIMORE, Italy 15 min  <b>5. Abstract ID 695 NOVEL AUTOANTIGEN PEPTIDE EPITOPES AS THERANOSTIC TARGETS IN INCURABLE AUTOIMMUNE BLISTERING DISEASES.</b> Simon D. Lytton 15 min  <b>6. Abstract ID 308 MTADV 5-MER peptide suppresses lung fibrosis, RA, IBD and MS mouse models and inhibits human fibroblasts biological functions by targeting SAA, which fuels fibrosis</b> David Naor, Israel 15 min</p>
12:00 – 14:00	<b>LUNCH BREAK, EXHIBITION, POSTER VIEWING</b>	<b>INDUSTRY SUPPORTED SESSION 12:15 - 13:45 NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT</b>	

14:00 – 15:30	<p><b>PS23 Pediatric and Autoimmunity</b>  <b>Chair 1</b> Sefi Uziel, Israel  <b>Chair 2</b> Tadej Avcin, Slovenia  <b>Chair 3</b> Angello Ravelli, Italy</p> <p>1. Next generation: what we know of children born to patients with systemic autoimmune diseases. Angela Tincani, Italy 15 min  2. APLA- SLE- TTP- MAS- what is the egg and what is the chicken? Sefi Uziel, Israel 15 min  3. Immune interventions in pre- and early- type 1 diabetes. Tadej Battelino, Slovenia 15 min  4. Autoimmunity in inborn errors of immunity and clinical approaches. Tadej Avcin, Slovenia 15 min  5. Monogenic causes of SLE and related clinical conditions. Alexandre Belot, France 15 min  6. Advances in the management of juvenile idiopathic arthritis. Angelo Ravelli, Italy 15 min</p>	<p><b>PS24 Mechanisms in Autoimmunity (Part 2)</b>  <b>Chair 1</b> Ferdinando Nicoletti, Italy  <b>Chair 2</b> Marcos López-Hoyos, Spain  <b>Chair 3</b> Christophe Jamin, France</p> <p>1. Abstract ID 702 Extracellular vesicles in autoimmunity. Polona Žigon, Slovenia 15 min  2. Auto and allo-immunity in solid organ transplantation. Risk for humoral graft rejection. Marcos López-Hoyos, Spain 15 min  3. Abstract ID 265 TAKING THE AUTOIMMUNE STING OUT OF PD-1 CHECKPOINT INHIBITION TO SUPPRESS CANCER GROWTH Michael Agrez 15 min  4. Abstract ID 309 TYPE 2 NKT CELLS DIRECTED IMMUNE REGULATORY MECHANISM IN LUPUS NEPHRITIS Vipin Kumar 15 min  5. Abstract ID 319 IMMUNE-CHECKPOINT INHIBITION AND AUTOIMMUNITY: YIN AND YANG Zoltan Szekanecz 15 min  6. Abstract ID 643 THE MOLECULAR INTERPLAY BETWEEN THE TRANSCRIPTION FACTORS ETS-2 AND FOXP3 IN EFFECTOR AND REGULATORY CD4+ T-CELLS IS INVOLVED IN THE DEVELOPMENT OF MULTIPLE SCLEROSIS (MS) Athanasia Mouzaki 15 min</p>	<p><b>PS25 Diagnostics in Autoimmunity</b>  <b>Chair 1</b> Nicola Bizzaro, Italy  <b>Chair 2</b> Torsten Matthias  <b>Chair 3</b> Maria Infantino, Italy</p> <p>1. EULAR/ACR 2019 SLE classification criteria – lessons learned in the first five years. Martin Aringer, Germany 15 min  2. Critical issues in autoantibody tests used as classification criteria for autoimmune diseases. Nicola Bizzaro, Italy 15 min  3. Circulating calprotectin: a marker gaining awareness. Maria Infantino, Italy  4. The use of advanced infrared spectroscopy for diagnosis of rheumatic disorders (fibromyalgia and rheumatoid arthritis). Boris Gilburd, Israel 15 min  5. Abstract 371 Subclinical and clinical markers in multiple sclerosis patients for prognosis and personalized therapy. Santa Rasa-Dzelzkaleja, Latvia 15 min  6. Abstract ID 647 IDENTIFICATION OF NOVEL ANTIGENIC TARGETS USING ANTIBODY PROFILING IN SPINAL CORD INJURY PATIENTS Astrid Poes 15 min</p>
15:30 – 15:45	SHORT BREAK		
15:45 – 16:45	<p><b>PS26 Pearls in Autoimmunity 2023</b>  <b>Chair 1</b> Amir Tanay, Israel  <b>Chair 2</b> Otávio Marques, Brazil  <b>Chair 3</b> Luc Mouthon, France</p> <p>1. COVID-19 vaccine related autoimmune rheumatic diseases. Michael Ehrenfeld, Israel 15 min  2. Harnessing the power of AI in medical research &amp; patient treatment. Yoad Dvir, Israel 15 min  3. Allergy and Autoimmunity, revisited "through the looking glass". Amir Tanay, Israel 15 min  4. Is the syndrome of postural orthostatic tachycardia autoimmune ? (results and review) Zora Lazurova, Slovakia 15 min</p>	<p><b>PS27 Nutrition and Life Style in Autoimmunity</b>  <b>Chair 1</b> Pedro Bastos, Sweden  <b>Chair 2</b> Vania Borba, Portugal  <b>Chair 3</b> Carina Benzvi, Israel</p> <p>1. Emerging role of Nutrition in the prevention and treatment of autoimmune diseases and immunosenescence. Vania Borba, Portugal 15 min  2. The food additive: microbial transglutaminase is a potential inducer of autoimmune diseases. Aaron Lerner, Israel 15 min  3. Lifestyle triggers of neuroinflammation. Pedro Bastos, Sweden 15 min  4. Abstract ID 292 THE RELATIONSHIP BETWEEN FIBROMYALGIA AND NUTRITION- AN UP TO DATE REVIEW OF THE LITERATURE Mohammad Adawi 15 min</p>	<p><b>PS28 Thyroid and Endocrine System</b>  <b>Chair 1</b> Alessandro Antonelli, Italy  <b>Chair 2</b> Ifigania Kostoglou–Athanassiou, Greece  <b>Chair 3</b> Roberto Giacomelli, Italy</p> <p>1. Graves' Ophthalmopathy epidemiology, pathogenesis and new therapies. Alessandro Antonelli, Italy 15 min  2. Vitamin D levels in Slovak women with autoimmune thyroid disease. Ivica Lazurova, Slovakia 15 min  3. Thyroid autoimmunity and COVID-19. Ifigania Kostoglou–Athanassiou, Greece 15 min  4. The potential role of Prolactin in A.S.I.A. Luis Javier Jara, Mexico 15 min</p>
16:45 – 17:15	COFFEE BREAK, EXHIBITION, POSTER VIEWING		
17:15 – 18:30	<p><b>PS29 Pathogenesis of Autoimmune Condition</b>  <b>Chair 1</b> Stefania Croci, Italy  <b>Chair 2</b> Tadej Battelino, Slovenia  <b>Chair 3</b> Dominique Farge, France</p> <p>1. Hyperferritinemia as a marker of worse outcome in patients with COVID-19 at hospital admission. Gisele Zandman-Goddard, Israel 15 min  2. Checkpoint proteins as a gate between autoimmune rheumatic diseases and cancer. Maurizio Cutolo, Italy 15 min  3. Update on checkpoint inhibitors induced autoimmunity. Michael Ehrenfeld, Israel 15 min  4. Eosinophilic fasciitis: from diagnosis to treatment. Luc Mouthon, France 15 min  5. Abstract ID 687 ANTI-CITRULLINATED HISTONE ANTIBODY CIT-013, A DUAL ACTION THERAPEUTIC FOR NEUTROPHIL EXTRACELLULAR TRAP ASSOCIATED AUTOIMMUNE DISEASES Annemarie Kip, 15 min</p>	<p><b>PS30 Kidney and Autoimmunity</b>  <b>Chair 1</b> Chaim Putterman, Israel  <b>Chair 2</b> Sylviane Muller, France  <b>Chair 3</b> Gasper Markelj, Slovenia</p> <p>1. Update on therapy of lupus nephritis with special focus on refractory forms. Dario Roccatello, Italy 15 min  2. Long term renal outcome in a cohort of Portuguese Lupus patients. Carlos Vasconcelos, Portugal 15 min  3. The CD6/ALCAM pathway as a novel biomarker and treatment target in lupus nephritis. Chaim Putterman, Israel 15 min  4. Difficult to treat systemic lupus erythematosus. Marta Mosca, Italy 15 min  5. Is Protocol Biopsy Required in Lupus Nephritis? Mariele Gatto, Italy 15 min</p>	<p><b>PS31 ICAP Session : Focus on the clinical relevance of the HEp-2 IFA (ANA) test</b>  <b>Chair 1</b> - Luis Andrade, Brazil  <b>Chair 2</b> - Lucile Musset, France</p> <p>1. Novel clinically relevant patterns and evolution of the ICAP classification tree Luis Andrade, Brazil, 20 min  2. Practical difficulties in fitting some images into the ICAP classification tree Jan Damoiseaux, Netherlands 20 minutes  3. Multiple, mixed, and composite patterns Luis Andrade, Brazil 15 minutes  4. Frequently Asked Questions for ICAP Maria Infantino, Italy 20 minutes</p>